Stay updated on Combining MK-3475 and SBRT in Metastatic Melanoma or NSCLC Clinical Trial
Sign up to get notified when there's something new on the Combining MK-3475 and SBRT in Metastatic Melanoma or NSCLC Clinical Trial page.

Latest updates to the Combining MK-3475 and SBRT in Metastatic Melanoma or NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe ClinicalTrials.gov record for a completed Yale study of pembrolizumab (MK-3475) combined with stereotactic radiotherapy in metastatic melanoma and NSCLC is now displayed. It includes the study plan, participant criteria, results, and a link to the study protocol.SummaryDifference53%

- Check13 days agoChange DetectedThe site footer’s revision identifier was updated from v3.7.2 to v3.8.0 while the page continued to show a 403 error.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide NIH notice announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error with a minimal layout and a Home link, replacing the previous study content.SummaryDifference19%

- Check62 days agoChange DetectedPage revision updated from v3.6.6 to v3.7.0, indicating a new version of the page. No study details or content appear to be changed.SummaryDifference0.1%

Stay in the know with updates to Combining MK-3475 and SBRT in Metastatic Melanoma or NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining MK-3475 and SBRT in Metastatic Melanoma or NSCLC Clinical Trial page.